A study of indefinite for dysplasia in Barrett's oesophagus: Reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (-methylacyl-CoA-racemase)

Histopathology

Volumn 56, Issue 7, 2010, Pages 900-907

  Sonwalkar, Sunil A ^a   Rotimi, Olorunda ^b   Scott, Nigel ^b   Verghese, Eldo ^b   Dixon, Mike ^b   Axon, Anthony T R A ^c   Everett, Simon M ^c  

^a CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b Department of Histopathology ^*  (United Kingdom)

^c Centre for Digestive Diseases   (United Kingdom)

Author keywords

methylacyl CoA racemase; Barrett's oesophagus; Dysplasia; Indefinite for dysplasia; Progression

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; ISOMERASE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ESOPHAGUS TUMOR; HYPERPLASIA; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PRECANCER; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OBSERVER VARIATION; PRECANCEROUS CONDITIONS; RACEMASES AND EPIMERASES;

EID: 77953207500     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03571.x     Document Type: Article

References (24)

1. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol. 1997 92 212 215.
2. Conio M, Cameron AJ, Romero Y et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001 48 304 309.
3. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann. Surg. Oncol. 2006 13 12 30.
4. McArdle JE, Lewin KJ, Randall G, Weinstein W. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum. Pathol. 1992 23 479 482.
5. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983 14 931 968.
6. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002 51 130 131.
7. Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988 19 166 178.
8. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 1999 50 23 26. (Pubitemid 29323284)
9. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 2000 95 3383 3387.
10. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 2001 32 368 378.
11. Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002 51 671 676.
12. Sagan C, Flejou JF, Diebold MD, Potet F, Le Bodic MF. [Reproducibility of histological criteria of dysplasia in Barrett mucosa]. Gastroenterol. Clin. Biol. 1994 18 (1 Pt 2 D31 D34.
13. Downs-Kelly E, Mendelin JE, Bennett AE et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's oesophagus biopsies. Am. J. Gastroenterol. 2008 9 2333 2340.
14. Kerkhof M, van Dekken H, Steyeberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007 50 920 927.
15. Jiang Z, Fanger GR, Woda BA et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum. Pathol. 2003 34 792 796.
16. Jiang Z, Wu CL, Woda BA et al. P504Salpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am. J. Surg. Pathol. 2002 26 1169 1174.
17. Luo J, Zha S, Gage WR et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002 62 2220 2226.
18. Rubin MA, Zhou M, Dhanasekaran SM et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002 287 1662 1670.
19. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 2006 30 871 877.
20. Lisovsky MFO, Bhuiya T. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum. Pathol. 2006 37 1601 1606.
21. Sträter J, Wiesmüller C, Perner S, Kuefer R, Möller P. Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia. Histopathology 2008 52 399 402.
22. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006 55 442.
23. Schlemper RJ, Dawsey SM, Itabashi M et al. Differences in diagnostic criteria for esophageal squamous cell carcinoma between Japanese and Western pathologists. Cancer 2000 88 996 1006.
24. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 2001 32 379 388.